Abstract
Migraine and cluster headache are primary headache disorders commonly encountered in clinical practice. Despite the profound disability caused by these primary headache disorders, available acute and preventive treatment options are limited. Recent understanding of headache pathophysiology has led to the development of new drug formulations and novel drug targets that are extremely promising. This article will highlight several of the new treatments that are currently under investigation including novel delivery mechanisms of already existing medications, calcitonin gene-related peptide (CGRP) receptor antagonists, antibodies to CGRP and its receptor, serotonin receptor agonists, transient receptor potential vanilloid receptor modulators, orexin receptor antagonists, glial cell modulators, and neuromodulation. If data is supportive, these therapies will be welcome additions to the headache specialist's armamentarium.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S89-S97 |
| Journal | Neurological Sciences |
| Volume | 35 |
| Issue number | SUPPL. 1 |
| DOIs | |
| State | Published - May 2014 |
Keywords
- CGRP
- Headache therapy pipeline
- Migraine treatment
- Neuromodulation
- Novel delivery mechanisms
ASJC Scopus subject areas
- Dermatology
- Clinical Neurology
- Psychiatry and Mental health
